Concepedia

Author

Estefanía Rojo-Bustamante

Universidad de NavarraORCID

Also Known As

Estefania Rojo-Bustamante, Estefanía Rojo-Bustamante

9

Publications

325

Citations

6

H-Index

16

Concepts

All Affiliations

Universidad de NavarraNavarre Institute of Health ResearchUniversitat de BarcelonaBiomedical Research Networking Center on Neurodegenerative Diseases
ER

About

Estefanía Rojo-Bustamante is an author at Universidad de Navarra specializing in medicine, neurology, and neuropharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

304

2

Neurology

4

4

260

3

Social Sciences

1

1

27

4

Biochemistry

1

1

69

5

Cell Biology

1

1

44

Estefanía Rojo-Bustamante

×

6

Publications

321

Citations

6

H-Index

YearCitations

GPR55: A therapeutic target for Parkinson's disease?

Marta Celorrio, Estefanía Rojo-Bustamante, Diana Fernández‐Suárez,

Neuropharmacology

2017

102

Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson’s disease

Marta Celorrio, Diana Fernández‐Suárez, Estefanía Rojo-Bustamante,

Brain Behavior and Immunity

2016

69

Pharmacologic antagonism of dopamine receptor D3 attenuates neurodegeneration and motor impairment in a mouse model of Parkinson's disease

Daniela Elgueta, Marta Aymerich, Francisco Contreras,

Neuropharmacology

2016

62

Neuroprotective Effect of JZL184 in MPP+-Treated SH-SY5Y Cells Through CB2 Receptors

Marta Aymerich, Estefanía Rojo-Bustamante, Carmen Molina,

Molecular Neurobiology

2015

44

The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia

Estefanía Rojo-Bustamante, Miguel Angel Abellanas, Pedro Clavero,

Neurobiology of Disease

2018

27

CB2 Receptors and Neuron–Glia Interactions Modulate Neurotoxicity Generated by MAGL Inhibition

Estefanía Rojo-Bustamante, Ignacio Íñigo-Marco, Miguel Angel Abellanas,

Biomolecules

2020

17

Page 1